{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:22:50Z","timestamp":1762168970950,"version":"build-2065373602"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Biotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Adenovirus is one of the most attractive viral vectors for therapeutic vaccines and gene therapy with the caveat that replication-competent adenoviruses (RCA) can be produced. To remediate this problem, engineered A-549 adenoviral vector complementing cells (SF-BMAdR cells) were previously generated by our organization for the production of E1-deleted adenoviral vectors without RCA. However, the production process remained to be improved for high titer production and scalability, as cost-effective and scalable biomanufacturing processes are critical for commercializing adenovirus-based vaccines and gene therapy. In this study, we first explored the potential of batch and fed-batch culture to increase maximum cell density and virus productivity by evaluating four different commercially available serum-free media and their combinations, and several feeds. A mixture (1:1) of two culture media improved the maximum cell density from 2.8\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    cells\/mL obtained in the current batch culture to 4.2\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    cells\/mL, and increased the virus productivity by 70% at a titer of 1.5\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    vp\/mL. The fed-batch culture process, however, did not yield a significant improvement in either the maximum cell density or virus productivity. In contrast, batch culture with one medium replacement not only increased the cell growth but also resulted in an additional 70% improvement in the virus productivity at 2.6\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    vp\/mL. The virus productivity was further increased to 6.3\u2009\u00d7\u200910\n                    <jats:sup>10<\/jats:sup>\n                    vp\/mL in a 3\u2009L bioreactor perfusion culture infected at 7.0\u2009\u00d7\u200910\n                    <jats:sup>6<\/jats:sup>\n                    cells\/mL. This titer is 7.5 folds of the titer obtained in the current process. This study demonstrated the potential for a drastic improvement in the productivity of RCA-free adenovirus in the SF-BMAdR culture process. Furthermore, various processes developed fulfill different operational needs in manufacturing of RCA-free adenovirus to meet the increasing demands for therapeutic vaccines and gene therapy.\n                  <\/jats:p>","DOI":"10.1186\/s12896-025-01051-8","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:06:53Z","timestamp":1762168013000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Process development for high-titer production of adenovirus devoid of replication-competent particles in suspension-adapted complementing A549 cell culture"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-3170","authenticated-orcid":false,"given":"Chun Fang","family":"Shen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elodie","family":"Burney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9nald","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Loignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"7","key":"1051_CR1","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s12275-024-00159-4","volume":"62","author":"A Park","year":"2024","unstructured":"Park A, Lee JY. Adenoviral vector system: A comprehensive overview of constructions, therapeutic applications and Host responses. J Microbiol. 2024, Jul;62(7):491\u2013509. https:\/\/doi.org\/10.1007\/s12275-024-00159-4. Epub 2024 Jul 22. PMID: 39037484.","journal-title":"JMicrobiol"},{"issue":"2","key":"1051_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3390\/vaccines11020432","volume":"11","author":"VP Chavda","year":"2023","unstructured":"Chavda VP, Bezbaruah R, Valu D, Patel B, Kumar A, Prasad S, Kakoti BB, Kaushik A, Jesawadawala M. Adenoviral vector-based vaccine platform for COVID-19: Current status. Vaccines (Basel). 2023, Feb, 13;11(2):432. https:\/\/doi.org\/10.3390\/vaccines11020432. PMID: 36851309; PMCID: PMC9965371.","journal-title":"Vaccines (Basel)"},{"issue":"12","key":"1051_CR3","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.3390\/v15122378","volume":"15","author":"PD Trivedi","year":"2023","unstructured":"Trivedi PD, Byrne BJ, Corti M. Evolving horizons: Adenovirus vectors\u2019 timeless influence on cancer, gene therapy and vaccines. Viruses. 2023, Dec, 3;15(12):2378. https:\/\/doi.org\/10.3390\/v15122378. PMID: 38140619; PMCID: PMC10747483.","journal-title":"Viruses"},{"issue":"13","key":"1051_CR4","doi-asserted-by":"publisher","first-page":"963049","DOI":"10.3389\/fimmu.2022.963049","volume":"31","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Zhao Z, Wang Y, Wu S, Wang B, Zhang J, Song X, Chen Y, Lv P, Hou L. Comparative immunogenicity analysis of intradermal versus intramuscular immunization with a recombinant human adenovirus type 5 vaccine against Ebola virus. Front Immunol. 2022, Aug;31(13):963049. https:\/\/doi.org\/10.3389\/fimmu.2022.963049. PMID: 36119119; PMCID: PMC9472118","journal-title":"Front Immunol"},{"issue":"8","key":"1051_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.3390\/v2081681","volume":"2","author":"I Kovesdi","year":"2010","unstructured":"Kovesdi I, Hedley SJ. Adenoviral producer cells. Viruses. 2010, Aug;2(8):1681\u2013703. https:\/\/doi.org\/10.3390\/v2081681. Epub 2010 Aug 16. PMID: 21994701; PMCID: PMC3185730","journal-title":"Viruses"},{"issue":"9","key":"1051_CR6","doi-asserted-by":"publisher","first-page":"796991","DOI":"10.3389\/fbioe.2021.796991","volume":"13","author":"E Tan","year":"2021","unstructured":"Tan E, Chin CSH, Lim ZFS, Ng SK. HEK293 cell line as a platform to produce recombinant proteins and viral vectors. Front Bioeng Biotechnol. 2021, Dec;13(9):796991. https:\/\/doi.org\/10.3389\/fbioe.2021.796991. PMID: 34966729; PMCID: PMC8711270","journal-title":"Front BioengBiotechnol"},{"issue":"2","key":"1051_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.ymthe.2006.02.020","volume":"14","author":"D Farson","year":"2006","unstructured":"Farson D, Tao L, Ko D, Li Q, Brignetti D, Segawa K, Mittelstaedt D, Harding T, Yu DC, Li Y. Development of novel E1-complementary cells for adenoviral production free of replication-competent adenovirus. Mol Ther. 2006, Aug;14(2):305\u201311. https:\/\/doi.org\/10.1016\/j.ymthe.2006.02.020. Epub 2006 May 12. PMID: 16697707","journal-title":"MolTher"},{"key":"1051_CR8","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.jviromet.2014.08.013","volume":"208","author":"R Gilbert","year":"2014","unstructured":"Gilbert R, Guilbault C, Gagnon D, Bernier A, Bourget L, Elahi SM, Kamen A, Massie B. Establishment and validation of new complementing cells for production of E1-deleted adenovirus vectors in serum-free suspension culture. J Virol Methods. 2014, Nov;208:177\u201388. https:\/\/doi.org\/10.1016\/j.jviromet.2014.08.013. Epub 2014 Aug 23. PMID: 25159033","journal-title":"J Virol Methods"},{"issue":"11","key":"1051_CR9","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.3390\/v15112152","volume":"15","author":"SM Elahi","year":"2023","unstructured":"Elahi SM, Jiang J, Nazemi-Moghaddam N, Gilbert R. A method to generate and rescue recombinant adenovirus devoid of replication-competent particles in animal-origin-free culture medium. Viruses. 2023, Oct, 25;15(11):2152. https:\/\/doi.org\/10.3390\/v15112152. PMID: 38005830; PMCID: PMC10674172","journal-title":"Viruses"},{"issue":"5","key":"1051_CR10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3390\/vaccines12050524","volume":"12","author":"CF Shen","year":"2024","unstructured":"Shen CF, Rodenbrock A, Lanthier S, Burney E, Loignon M. Optimization of culture media and feeding strategy for high titer production of an adenoviral vector in HEK 293 fed-batch culture. Vaccines (Basel). 2024, May, 10;12(5):524. https:\/\/doi.org\/10.3390\/vaccines12050524. PMID: 38793775; PMCID: PMC11125598","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"1051_CR11","doi-asserted-by":"publisher","first-page":"e2300244","DOI":"10.1002\/biot.202300244","volume":"19","author":"CF Shen","year":"2024","unstructured":"Shen CF, Burney E, Gilbert R, Elahi SM, Parato K, Loignon M. Development, optimization, and scale-up of suspension vero cell culture process for high titer production of oncolytic herpes simplex virus-1. Biotechnol J. 2024. Jan;19(1):e2300244. https:\/\/doi.org\/10.1002\/biot.202300244. Epub 2023 Oct 15. PMID: 37767876","journal-title":"BiotechnolJ"},{"issue":"755(1\u20132)","key":"1051_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0378-4347(00)00597-1","volume":"5","author":"V Klyushnichenko","year":"2001","unstructured":"Klyushnichenko V, Bernier A, Kamen A, Harmsen E. Improved high-performance liquid chromatographic method in the analysis of adenovirus particles. J Chromatogr B Biomed sci Appl. 2001. May;5(755(1\u20132)):27\u201336. https:\/\/doi.org\/10.1016\/s0378-4347(00)00597-1. PMID: 11393714","journal-title":"J Chromatogr B Biomed sciappl"},{"issue":"8","key":"1051_CR13","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1007\/s00449-022-02737-5","volume":"45","author":"CF Shen","year":"2022","unstructured":"Shen CF, Tremblay S, Sabourin-Poirier C, Burney E, Broussau S, Manceur A, Rodenbrock A, Voyer R, Loignon M, Ansorge S, Gilbert R. Culture media selection and feeding strategy for high titer production of a lentiviral vector by stable producer clones cultivated at high cell density. Bioprocess biosysteng. 2022, Aug;45(8):1267\u201380. https:\/\/doi.org\/10.1007\/s00449-022-02737-5. Epub 2022 Jun 27. PMID: 35758994; PMCID: PMC9363386","journal-title":"Bioprocess biosysteng"},{"issue":"7\u20138","key":"1051_CR14","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s0734-9750(02)00030-7","volume":"20","author":"I Nadeau","year":"2003","unstructured":"Nadeau I, Kamen A. Production of adenovirus vector for gene therapy. Biotechnol Adv. 2003, Jan;20(7\u20138):475\u201389. https:\/\/doi.org\/10.1016\/s0734-9750(02)00030-7. PMID: 14550017","journal-title":"Biotechnol Adv"},{"key":"1051_CR15","doi-asserted-by":"publisher","unstructured":"Kamen A, Henry O. Development and optimization of an adenovirus production process. J GeneMed. 2004, Feb;6Suppl, 1:S184\u201392. https:\/\/doi.org\/10.1002\/jgm.503. PMID: 14978761","DOI":"10.1002\/jgm.503"},{"issue":"5 Pt 1","key":"1051_CR16","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1006\/mthe.2001.0323","volume":"3","author":"P Ng","year":"2001","unstructured":"Ng P, Beauchamp C, Evelegh C, Parks R, Graham FL. Development of a FLP\/frt system for generating helper-dependent adenoviral vectors. Mol Ther. 2001, May;3(5 Pt 1):809\u201315. https:\/\/doi.org\/10.1006\/mthe.2001.0323. PMID: 11356086","journal-title":"Mol Ther"},{"issue":"25","key":"1051_CR17","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.omtm.2022.03.004","volume":"7","author":"R Nilson","year":"2022","unstructured":"Nilson R, L\u00fcbbers O, Schmidt CQ, Rojewski M, Zeplin PH, Funk W, Schrezenmeier H, Kritzinger A, Kochanek S, Krutzke L. Hexon modification of human adenovirus type 5 vectors enables efficient transduction of human multipotent mesenchymal stromal cells. Mol Ther Methods clin dev. 2022, Mar;7(25):96\u2013110. https:\/\/doi.org\/10.1016\/j.omtm.2022.03.004. PMID: 35402633; PMCID: PMC8956844","journal-title":"Mol Ther Methods clindev"},{"key":"1051_CR18","doi-asserted-by":"publisher","unstructured":"Nichols WW, Lardenoije R, Ledwith BJ, Brouwer K, Manam S, Vogels R, Kaslow D, Zuidgeest D, Bett AJ, Chen L, van der Kaaden M, Galloway SM, Hill RB, Machotka SV, Anderson CA, Lewis J, Martinez D, Lebron J, Russo C, Valerio D, Bout A. Propagation of adenoviral vectors: Use of PER. C6 cells. Adenoviral Vectors For Gene Ther. 2002;129\u201366. https:\/\/doi.org\/10.1016\/B978-012199504-1\/50007-9. Epub 2007 May 9.PMCID: PMC7271171","DOI":"10.1016\/B978-012199504-1\/50007-9"},{"issue":"47","key":"1051_CR19","doi-asserted-by":"publisher","first-page":"6996","DOI":"10.1016\/j.vaccine.2019.07.003","volume":"37","author":"CF Shen","year":"2019","unstructured":"Shen CF, Guilbault C, Li X, Elahi SM, Ansorge S, Kamen A, Gilbert R. Development of suspension adapted vero cell culture process technology for production of viral vaccines. Vaccine. 2019. Nov, 8;37(47):6996\u20137002. https:\/\/doi.org\/10.1016\/j.vaccine.2019.07.003. Epub 2019 Jul 6. PMID: 31288997","journal-title":"Vaccine"},{"key":"1051_CR20","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/10_2018_59","volume":"165","author":"B Kelley","year":"2018","unstructured":"Kelley B, Kiss R, Laird M. A different perspective: How much innovation is really needed for monoclonal antibody production using mammalian cell technology? Adv Biochem Eng biotechnol. 2018;165:443\u201362. https:\/\/doi.org\/10.1007\/10_2018_59. PMID: 29721583","journal-title":"Adv Biochem engbiotechnol"},{"issue":"4","key":"1051_CR21","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00253-022-12342-x","volume":"107","author":"WJ Xu","year":"2023","unstructured":"Xu WJ, Lin Y, Mi CL, Pang JY, Wang TY. Progress in fed-batch culture for recombinant protein production in CHO cells. Appl Microbiol Biotechnol. 2023, Feb;107(4):1063\u201375. https:\/\/doi.org\/10.1007\/s00253-022-12342-x. Epub 2023 Jan 17. PMID: 36648523; PMCID: PMC9843118","journal-title":"Appl MicrobiolBiotechnol"},{"key":"1051_CR22","doi-asserted-by":"publisher","unstructured":"Elias CB, Zeiser A, B\u00e9dard C, Kamen AA. Enhanced growth of sf-9 cells to a maximum density of 5.2 x 10(7) cells per mL and production of beta-galactosidase at high cell density by fed batch culture. Biotechnol Bioeng. 2000. May, 20;68(4):381\u201388. https:\/\/doi.org\/10.1002\/(sici)1097-0290(20000520)68:4%3C381:aid-bit3%3E3.0.co;2-d. PMID: 10745206","DOI":"10.1002\/(sici)1097-0290(20000520)68:4%3C381:aid-bit3%3E3.0.co;2-d"},{"key":"1051_CR23","unstructured":"Aunins JG. Viral vaccine production in cell culture. In: Encyclopedia of cell technology. Hoboken, NJ, USA: John Wiley Sons, Inc; 2003, ISBN 9780471250579"},{"issue":"5","key":"1051_CR24","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1007\/s00253-015-7267-9","volume":"100","author":"F Tapia","year":"2016","unstructured":"Tapia F, V\u00e1zquez-Ram\u00edrez D, Genzel Y, Reichl U. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production. Appl Microbiol Biotechnol. 2016. Mar;100(5):2121\u201332. https:\/\/doi.org\/10.1007\/s00253-015-7267-9. Epub 2016 Jan 13. PMID: 26758296; PMCID: PMC4756030","journal-title":"Appl MicrobiolBiotechnol"},{"issue":"1","key":"1051_CR25","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/btpr.286","volume":"26","author":"CF Shen","year":"2010","unstructured":"Shen CF, Voyer R, Tom R, Kamen A. Reassessing culture media and critical metabolites that affect adenovirus production. Biotechnol Prog. 2010, Jan-Feb;26(1):200\u201307. https:\/\/doi.org\/10.1002\/btpr.286. PMID: 19728394","journal-title":"BiotechnolProg"},{"key":"1051_CR26","unstructured":"Xie L, Goochee CF. Methods of adenovirus production. US patent: 7344873B2 year 2008"},{"issue":"7","key":"1051_CR27","doi-asserted-by":"publisher","first-page":"3025","DOI":"10.1007\/s00253-019-09694-2","volume":"103","author":"D V\u00e1zquez-Ram\u00edrez","year":"2019","unstructured":"V\u00e1zquez-Ram\u00edrez D, Jordan I, Sandig V, Genzel Y, Reichl U. High titer MVA and influenza a virus production using a hybrid fed-batch\/perfusion strategy with an ATF system. Appl Microbiol Biotechnol. 2019, Apr;103(7):3025\u201335. https:\/\/doi.org\/10.1007\/s00253-019-09694-2. Epub 2019 Feb 23. PMID: 30796494; PMCID: PMC6447503","journal-title":"Appl MicrobiolBiotechnol"},{"issue":"19","key":"1051_CR28","doi-asserted-by":"publisher","first-page":"7251","DOI":"10.1007\/s00253-021-11561-y","volume":"105","author":"MD Hein","year":"2021","unstructured":"Hein MD, Chawla A, Cattaneo M, Kupke SY, Genzel Y, Reichl U. Cell culture-based production of defective interfering influenza a virus particles in perfusion mode using an alternating tangential flow filtration system. Appl Microbiol Biotechnol. 2021, Oct;105(19):7251\u201364. https:\/\/doi.org\/10.1007\/s00253-021-11561-y. Epub 2021 Sep 14. PMID: 34519855; PMCID: PMC8437742","journal-title":"Appl MicrobiolBiotechnol"}],"container-title":["BMC Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12896-025-01051-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12896-025-01051-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:06:56Z","timestamp":1762168016000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcbiotechnol.biomedcentral.com\/articles\/10.1186\/s12896-025-01051-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1051"],"URL":"https:\/\/doi.org\/10.1186\/s12896-025-01051-8","relation":{},"ISSN":["1472-6750"],"issn-type":[{"value":"1472-6750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"20 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This study has been published with the approval of all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"119"}}